Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.38 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.37 |
| D008171 | Lung Diseases, NIH | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Pulmonary obstruction HPO | 0.38 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.37 |
| HP:0002088 | Abnormal lung morphology HPO | 0.14 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Description: Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h
Measure: Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h Time: 12 weeksDescription: Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12
Measure: Average FEV1 AUC0-4h post-dose at Week 12 Time: 12 weeksDescription: Change from baseline in Peak FEV1 over 4 hours post dose at Week 12
Measure: Peak FEV1 over 4 hours post dose at Week 12 Time: 12 weeksDescription: Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24
Measure: Weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24 Time: 24 weeksDescription: Change from baseline of SGRQ total score at Week 24
Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Week 24 Time: 24 weeksDescription: Change from baseline of Morning trough FEV1 at Week 12
Measure: Morning trough FEV1 at Week 12 Time: 12 weeksDescription: The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.
Measure: St. George's Respiratory Questionnaire (SGRQ) Time: 24 weeksDescription: Change from baseline of Rescue medication use at Week 24
Measure: Rescue medication use at Week 24 Time: 24 weeksDescription: Transitional Dyspnea Index (TDI) at Week 24
Measure: Transitional Dyspnea Index (TDI) at Week 24 Time: 24 weeksDescription: Change from baseline Evening trough FEV1 at Week 12
Measure: Evening trough FEV1 at Week 12 Time: 12 weeksDescription: Change from baseline Peak FEV1
Measure: Peak FEV1 at Week 6 and Week 24 Time: 6 and 24 weeksDescription: Change from baseline morning trough FEV1
Measure: Morning trough FEV1 at Week 6 and Week 24 Time: 6 and 24 weeksDescription: Change from baseline evening trough FEV1
Measure: Evening trough FEV1 at Week 6 and Week 24 Time: 6 and 24 weeksDescription: Change from baseline FEV1 AUC0-4h
Measure: FEV1 AUC0-4h at Week 6 and Week 24 Time: 6 and 24 weeksDescription: Change from baseline E-RS Total Score
Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12 Time: 6 and 12 weeksDescription: Change from baseline SGRQ responder analysis
Measure: St. George's Respiratory Questionnaire (SGRQ) responder analysis at Week 6 and Week 12 Time: 6 and 12 weeksDescription: Change from baseline TDI
Measure: TDI at Week 6 and Week 12 Time: 6 and 12 WeeksDescription: Change from baseline of SGRQ total score at Weeks 6 and 12
Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12 Time: 6 Weeks and 12 weeksDescription: Change from baseline of Rescue medication use at Weeks 6 and 12
Measure: Rescue medication use at Weeks 6 and 12 Time: 12 weeksThe purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Description: Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h
Measure: Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h Time: 12 weeksDescription: Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12
Measure: Average FEV1 AUC0-4h post-dose at Week 12 Time: 12 weeksDescription: Change from baseline of Peak FEV1 over 4 hours post-dose at Week 12
Measure: Peak FEV1 over 4 hours post-dose at Week 12 Time: 12 weeksDescription: Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24
Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24 Time: 24 weeksDescription: Change from baseline of SGRQ total score at Week 24
Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Week 24 Time: 24 weeksDescription: Change from baseline of Morning trough FEV1 at Week 12
Measure: Morning trough FEV1 at Week 12 Time: 12 weeksDescription: The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.
Measure: St. George's Respiratory Questionnaire (SGRQ) responders at Week 24 Time: 24 weeksDescription: Change from baseline of Rescue medication use at Week 24
Measure: Rescue medication use at Week 24 Time: 24 weeksDescription: Transitional Dyspnea Index (TDI) at Week 24
Measure: Transitional Dyspnea Index (TDI) at Week 24 Time: 24 weeksDescription: Change from baseline Evening trough FEV1 at Week 12
Measure: Evening trough FEV1 at Week 12 Time: 12 weeksDescription: Change from baseline Peak FEV1
Measure: Peak FEV1 at Week 6 and Week 24 Time: 6 or 24 weeksDescription: Change from baseline morning trough FEV1
Measure: Morning trough FEV1 at Week 6 and Week 24 Time: 6 or 24 weeksDescription: Change from baseline evening trough FEV1
Measure: Evening trough FEV1 at Week 6 and Week 24 Time: 6 or 24 weeksDescription: Change from baseline FEV1 AUC0-4h
Measure: FEV1 AUC0-4h at Week 6 and Week 24 Time: 6 or 24 weeksDescription: Change from baseline E-RS Total Score
Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12 Time: 6 or 12 weeksDescription: Change from baseline SGRQ responder analysis
Measure: SGRQ responder analysis at Week 6 and Week 12 Time: 6 or 12 weeksDescription: Change from baseline TDI
Measure: TDI at Week 6 and Week 12 Time: 6 or 12 weeksDescription: Change from baseline of SGRQ total score
Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12 Time: 6 or 12 weeksDescription: Change from baseline of Rescue medication use
Measure: Rescue medication use at Weeks 6 and 12 Time: 6 or 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports